Jeito Capital | Activity | F4

Jeito Capital Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Team Change

Jeito Capital promoted Pascal Touchon to Partner, Claudio Costa-Neto to Partner/CSO, Annette Clancy to Operating Partner, Samit Hirawat to Operating Partner, and appointed Ana Leticia Maragno as Director of Translational Science.

Jeito Capital

Jeito CapitalJeito Capital

jeito.life

SEP 8, 2026

SEP 8, 2026

Team Change

Jeito Capital appointed Magdalena Jonikas (ex-Syncona Partner) as Partner and Anastasiya Sybirna (ex-F-Prime Capital) as Principal, both based in London, strengthening UK presence.

Jeito Capital

Jeito CapitalJeito Capital

jeito.lifeJUL 8, 2026

JUL 8, 2026

Investment

Jeito Capital co-led a $165M oversubscribed Series A financing in Bionyra Pharma to advance clinical-stage pipeline of next-generation biologics for immune-mediated inflammatory diseases.

Bionyra Pharma

Bionyra Pharma Jeito Capital

jeito.lifeJUN 22, 2026

JUN 22, 2026

Exit

Jeito Capital portfolio company Odyssey Therapeutics successfully completed an upsized IPO on Nasdaq, raising $304M. Jeito participated in the IPO.

Odyssey Therapeutics

Odyssey Therapeutics Jeito Capital

jeito.lifeMAY 12, 2026

MAY 12, 2026

Milestone

Portfolio company Odyssey Therapeutics priced an upsized $304M IPO and began trading on Nasdaq under ODTX.

Odyssey Therapeutics

Odyssey Therapeutics Jeito Capital

globenewswire.comMAY 8, 2026

MAY 8, 2026

Team Change

Jeito Capital appointed Elaine Caughey (ex-Blackstone Life Sciences Deputy COO) as Partner, Business Development and Investor Relations, and Sarah Shackelton (ex-Oxford Science Enterprises) as Partner, Talent.

Jeito Capital

Jeito CapitalJeito Capital

jeito.lifeMAY 5, 2026

MAY 5, 2026

Team Change

Appointed Elaine Caughey as Partner, Business Development and Investor Relations, and Sarah Shackelton as Partner, Talent.

Elaine Caughey and Sarah Shackelton join as Partners

Jeito Capital

businesswire.comMAY 5, 2026

MAY 5, 2026

Investment

Jeito Capital led an oversubscribed $75M Series C in Adcendo to advance its first- and best-in-class clinical ADC pipeline in oncology.

Adcendo

Adcendo Jeito Capital

jeito.lifeAPR 14, 2026

APR 14, 2026

New Fund

Jeito Capital hit a record $1.2B (€1B) close for Jeito II Fund, the largest raise ever achieved by a fully independent European biopharma-focused fund.

Jeito Capital

Jeito CapitalJeito Capital

jeito.lifeAPR 8, 2026

APR 8, 2026

New Fund

Closed Jeito II Fund at over EUR 1 billion (~$1.2B), the largest-ever raise by a fully independent European biopharma-focused fund, tripling AUM to EUR 1.6B.

Jeito II Fund

Jeito Capital

jeito.lifeAPR 8, 2026

biopharmadive.com

fiercebiotech.com

APR 8, 2026

Investment

Cornerstone investor in the oversubscribed $197M Series A second closing for Alveus Therapeutics (obesity and metabolic disease).

Alveus Therapeutics

Alveus Therapeutics Jeito Capital

biospace.comFEB 24, 2026

FEB 24, 2026

Team Change

Promoted Ksenija Pavletic to General Partner and Chief Commercial Officer.

Ksenija Pavletic promoted to General Partner

Jeito Capital

finance.yahoo.comOCT 2025

OCT 2025

Team Change

Promoted Mehdi Ainouche to Partner and Julien Elric to Senior Principal.

Mehdi Ainouche promoted to Partner; Julien Elric to Senior Principal

Jeito Capital

globenewswire.comMAY 12, 2025

MAY 12, 2025

Exit

Portfolio company HI-Bio (Human Immunology Biosciences) acquired by Biogen (~$1.15B upfront, up to $650M in milestones).

HI-Bio

HI-Bio Jeito Capital

investors.biogen.comJUL 2, 2024

JUL 2, 2024

Page 1 of 2